Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

Vaccine

Volumn 22, Issue 29-30, 2004, Pages 3993-4001

  Hsieh, Chia Jung ^a   Kim, Tae Woo ^a   Hung, Chien Fu ^a   Juang, Jeremy ^a   Moniz, Michelle ^a   Boyd, David A K ^a   He, Liangmei ^a   Chen, Pei Jer ^c   Chen, Chien Hung ^c   Wu, T C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Calreticulin; Cancer immunotherapy; Vaccinia vaccines

Indexed keywords

CALRETICULIN; CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; TUMOR ANTIGEN; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; WART VIRUS;

EID: 84984552535     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.057     Document Type: Article

References (48)

1. Moss B. Vaccinia virus: a tool for research and vaccine development [Review]. Science. 252(5013):1991;1662-1667
2. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer. 78(1):1998;41-45
3. Chen C.H., Suh K.W., Ji H., Choti M.A., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol. 33(1):2000;91-98
4. Lin K.Y., Guarnieri F.G., Staveley O.C.K.F., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1):1996;21-26
5. Meneguzzi G., Cerni C., Kieny M.P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181(1):1991;62-69
6. Kass E., Panicali D.L., Mazzara G., Schlom J., Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 61(1):2001;206-214
7. Borysiewicz L.K., Fiander A., Nimako M., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet. 347(9014):1996;1523- 1527
8. Scholl S.M., Balloul J.M., Le Goc G., et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 23(5):2000;570-580
9. McAneny D., Ryan C.A., Beazley R.M., Kaufman H.L. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol. 3(5):1996;495-500
10. Eder J.P., Kantoff P.W., Roper K., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 6(5):2000;1632-1638
11. Sanda M.G., Smith D.C., Charles L.G., et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 53(2):1999;260-266
12. Horig H., Lee D.S., Conkright W., et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. 49(9):2000;504-514
13. Conry R.M., Allen K.O., Lee S., Moore S.E., Shaw D.R., LoBuglio A.F. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res. 6(1):2000;34-41
14. Nash P.D., Opas M., Michalak M. Calreticulin: not just another calcium-binding protein. Mol Cell Biochem. 135(1):1994;71-78
15. Conway E.M., Liu L., Nowakowski B., Steiner-Mosonyi M., Ribeiro S.P., Michalak M. Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J Biol Chem. 270(28):1995;17011-17016
16. Basu S., Srivastava P.K. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med. 189(5):1999;797-802
17. Spee P., Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol. 27(9):1997;2441-2449
18. Sadasivan B., Lehner P.J., Ortmann B., Spies T., Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 5(2):1996;103-114
19. Pike S.E., Yao L., Setsuda J., et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood. 94(7):1999;2461-2468
20. Pike S.E., Yao L., Jones K.D., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 188(12):1998;2349-2356
21. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 36(2):1995;109-118
22. Hanahan D., Christofori G., Naik P., Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 32A(14):1996;2386- 2393
23. Cheng W.F., Hung C.F., Chai C.Y., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 108(5):2001;669-678
24. Hung C.F., Wu T.C. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther. 5(1):2003;20-24
25. Hung C.F., Cheng W.F., Hsu K.F., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61(9):2001;3698-3703
26. Wu T.-C., Guarnieri F.G., Staveley-O'Carroll K.F., et al. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. 92:1995;11671-11675
27. Chen C.H., Wang T.L., Hung C.F., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60(4):2000;1035-1042
28. Ji H., Wang T.-L., Chen C.-H., et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Human Gene Therapy. 10(17):1999;2727-2740
29. Restifo N.P., Bacik I., Irvine K.R., et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol. 154(9):1995;4414-4422
30. Fu T.M., Mylin L.M., Schell T.D., et al. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol. 72(2):1998;1469-1481
31. Boyle J.S., Brady J.L., Lew A.M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature. 392(6674):1998;408-411
32. Rice J., King C.A., Spellerberg M.B., Fairweather N., Stevenson F.K. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine. 17(23-24):1999;3030-3038
33. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264(5161):1994;961-965
34. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming [Review] [52 refs.]. Immunogenetics. 39(2):1994;93-98
35. Arnold D., Faath S., Rammensee H., Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182(3):1995;885-889
36. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269(5230):1995;1585-1588
37. Castellino F., Boucher P.E., Eichelberg K., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med. 191(11):2000;1957-1964
38. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14(3):2001;303-313
39. Xiao F., Wei Y., Yang L., et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 9(18):2002;1207-1213
40. Puhlmann M., Brown C.K., Gnant M., et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7(1):2000;66-73
41. Norbury C.C., Malide D., Gibbs J.S., Bennink J.R., Yewdell J.W. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol. 3(3):2002;265-271
42. Hung C.F., Cheng W.F., Chai C.Y., et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol. 166(9):2001;5733-5740
43. Hung C.F., Hsu K.F., Cheng W.F., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61(3):2001;1080-1088
44. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther, 2003 [in press].
45. Chen C.H., Wang T.L., Hung C.F., Pardoll D.M., Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 18(19):2000;2015-2022
46. Earl P.L., Moss B. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res Hum Retroviruses. 9(7):1993;589-594
47. Feltkamp M.C., Smits H.L., Vierboom M.P., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23(9):1993;2242-2249
48. Cheng W.F., Hung C.F., Hsu K.F., et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther. 12(3):2001;235-252